NDA 021386 · Novartis
Zometa
Zoledronic Acid · Iv (Infusion)
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 4, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Feb 22, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
363
118 Phase 3, 24 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2004 Supplement 1 · Efficacy LabelLetter
- Feb 22, 2002 Original approval · Type 6 - New Indication (no longer used) · priority review ReviewOther Important Information from FDALetter
1 products under this application
- ZOMETA · ZOLEDRONIC ACID EQ 4MG BASE/VIAL · INJECTABLE, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zoledronic Acid" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- HORIZON-PFT: Pivotal Fracture TrialPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00049829 · 7,700 participants · Start Jan 2002 · Primary completion Jun 2006
Drug: Zoledronic Acid · For: Osteoporosis
Sites: Birmingham, Alabama; Paradise Valley, Arizona; Tucson, Arizona · 60 sites in all
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00127205 · 6,097 participants · Start Jul 2005 · Primary completion Dec 2017
Drug: clodronate disodium; ibandronate sodium and 1 more · For: Breast Cancer
- Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-TrialPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT02181101 · 3,754 participants · Start Sep 2005 · Primary completion Sep 2013
Drug: FEC-DocGemzar adjuvant chemotherapy; FEC-Doc adjuvant chemotherapy and 2 more · For: Breast Neoplasms
Sites: Munich, Germany
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00556374 · 3,420 participants · Start Dec 18, 2006 · Primary completion Oct 7, 2014
Drug: Placebo; Denosumab and 2 more · For: Breast Cancer
Sites: Baden, Austria; Braunau am Inn, Austria; Dornbirn, Austria · 46 sites in all
- Trial of Parkinson's And Zoledronic AcidPivotal-lookingCompleted
California Pacific Medical Center Research InstituteAcademic, hospital or other
NCT03924414 · 2,721 participants · Start Nov 15, 2019 · Primary completion Feb 28, 2026
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj · For: Parkinson Disease; Osteoporosis; Parkinsonism and 6 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 77 sites in all
- The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture PatientsPivotal-lookingStatus unknown
The University of Hong KongAcademic, hospital or other
NCT05743179 · 2,692 participants (planned) · Start Dec 5, 2022 · Primary completion May 2025
Drug: Zoledronate · For: Hip Fractures; Pneumonia
Sites: Hong Kong, Hong Kong; Kwun Tong, Hong Kong; Sham Shui Po, Hong Kong · 5 sites in all
- Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)Pivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00145327 · 2,456 participants · Start May 2005 · Primary completion Nov 2009
Drug: Zoledronic Acid; Placebo · For: Osteoporosis
Sites: Tucson, Arizona; Little Rock, Arkansas; Beverly Hills, California · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K, Carducci M, Smith M, et al. · Lancet 2011 · Clinical Trial, Phase III, Comparative Study
- Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J, Lin X, Sun L, et al. · J Clin Endocrinol Metab 2024 · Randomized Controlled Trial, Comparative Study
- Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. · N Engl J Med 2007 · Multicenter Study, Randomized Controlled Trial
- Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.
Kobayashi T, Morimoto T, Ito K, et al. · Osteoporos Int 2024 · Meta-Analysis, Comparative Study
- Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT, Lipton A, Body JJ, et al. · J Clin Oncol 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, et al. · Lancet 2016 · Multicenter Study, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.